8 results about "Erysipelas" patented technology

The present invention relates to a combination of a first vaccine comprising a non-replicating immunogen of porcine erysipelothrix sp. And a non-replicating immunogen of porcine parvovirus and a second vaccine comprising a non-replicating immunogen of leptospira sp. And the first vaccine and the second vaccine are jointly injected into corium layers of a first injection part and a second injection part of the pig at different points to prophylactically treat the pig so as to resist swine erysipelothrix erysipelas infection, porcine parvovirus infection and leptospirosis infection.

The invention belongs to the technical field of traditional Chinese medicines, and provides a traditional Chinese medicine composition for treating erysipelas and a preparation method thereof. The traditional Chinese medicine composition comprises the following components: astragalus membranaceus, artemisia anomala, sappan wood, callicarpa macrophylla, winged euonymus twig, honeysuckle, purslane, lithospermum, sanguisorba officinalis, cacumen biotae and golden cypress. Pharmacodynamic experiments show that the traditional Chinese medicine composition obviously relieves lower limb swelling of erysipelas rats, reduces the content of NO in serum, increases the content of TNF-alpha in the serum, reduces the lesion score of lesion parts, and effectively improves related symptoms of erysipelas. The traditional Chinese medicine composition is wide in raw material source, easy to collect, simple in preparation process, high in safety, free of obvious adverse effects and free of adverse effects on the environment.

The present invention relates to the cosmetic use of phytosterols to protect and / or restore the skin microbiota and / or to prevent and / or reduce the unsightly, unpleasant, and / or uncomfortable manifestations of skin microbiota alteration. It further relates to a cosmetic treatment method comprising the topical application of phytosterols to at least one area of ​​skin, advantageously the scalp, to protect and / or restore the skin microbiota and / or to prevent and / or reduce the unsightly, unpleasant, and / or uncomfortable manifestations of skin microbiota alteration.Finally, it concerns phytosterols for their use in the treatment and / or prevention and / or reduction of the occurrence of a pathology associated with an alteration of the skin microbiota, in particular chosen from the group consisting of acne, psoriasis and bacterial and / or fungal infections, ulcers, herpes, boils, folliculitis, abscesses, sycosis, impetigo, ecthyma, erysipelas, mycoses such as candidiasis or dermatophytoses such as ringworm and / or scabies, pigmentary and / or acne scars as well as their combinations and / or in the treatment and / or prevention of superinfection of wounds and / or in the prevention of spots.

The application discloses an engineered bacillus subtilis strain for producing tagatose, a construction method and application thereof, and belongs to the technical field of bioengineering. The engineered strain takes bacillus subtilis as a host, co-expresses L-arabinose isomerase from Erysipelothrix larvae and beta-galactosidase from escherichia coli, and constructs the bacillus subtilis for co-expressing double enzymes through ribosome binding sites or promoters in series. The double-enzyme bacillus subtilis whole cell catalyzes lactose to produce D-tagatose, and the yield and conversion efficiency of D-tagatose are significantly improved after optimization of the enzymatic reaction. The application adopts single-strain double-enzyme co-expression and one-step whole-cell catalysis, uses low-cost lactose as a substrate, and has the advantages of mild reaction, less by-product, simplified process, no endotoxin safety hazard, and the like. The application solves the problems of low conversion rate, high substrate cost and complicated strain compounding in the prior art, and is suitable for industrialized production of food-grade D-tagatose.

The present invention relates generally to the use of a compound of formula (I) as defined herein as an active ingredient. Furthermore, the present invention relates to a method for inhibiting or preventing the growth of one or more microorganisms, and a method for inhibiting or reducing the conversion of sweat components to odorous compounds. The invention also relates to a compound of formula (I) as defined herein for use in the treatment of inflammation, post-inflammatory pigmentation, atopic dermatitis, bacterial vaginosis, tinea pedis, neonatal exfoliative dermatitis, contagious impetigo, furuncle and carbuncle, folliculitis, impetigo and / or erysipelas and for use as an antimicrobial agent, a mixture comprising one or two compounds of formula (I) as defined herein, and a mixture comprising one or two compounds of formula (I) as defined herein and one or more other antimicrobial agents. Finally, the present invention relates to a deodorant, a rinse-on product and a rinse-free product as defined herein.

The present invention relates to a vaccine comprising a non-replicating immunogen of swine erysipelothrix erysipelas and a non-replicating immunogen of porcine parvovirus, the use of a first vaccine in the prophylactic treatment of a pig against infection of erysipelothrix erysipelas and infection of porcine parvovirus by injecting the first vaccine into the corium layer of the pig.

A peptide-ionic liquid conjugate for the prevention and / or treatment of skin disorders. The peptide-ionic liquid conjugate comprises a cosmeceutical peptide comprising up to 10 amino acids and at least one ionic liquid comprising saturated or unsaturated hydrocarbon chain substituents from C1 to C18. The peptide-ionic liquid conjugates herein disclosed are suitable against skin disorders, such as, e.g., melanoma, non-melanoma skin cancers, diabetic foot ulcers, venous leg ulcers, pressure ulcers, acne, candidiasis, cellulitis, dermatophytoses, erysipelas, folliculitis, impetigo, psoriasis, rosacea, or eczema (atopic dermatitis), since they present potent activity against either antibiotic-susceptible strains or multidrug resistant clinical isolates of both Gram-positive and Gram-negative, a bactericidal type of action, anti-inflammatory and immunomodulatory effects, and collagenesis-inducing effects. Further disclosing a topical composition comprising the peptide-ionic liquid conjugates and uses thereof.

The invention relates to a traditional Chinese medicine liniment for relieving swelling and pain and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine preparations. The traditional Chinese medicine liniment is prepared from the following components in parts by weight: 40-60 parts of rheum officinale, 45-55 parts of radix angelicae, 50-55 parts of turmeric, 40-55 parts of golden cypress, 15-25 parts of rhizoma arisaematis, 15-20 parts of pericarpium citri reticulatae, 15-30 parts of rhizoma atractylodis, 20-25 parts of mangnolia officinalis, 15-25 parts of liquorice and 80-120 parts of radices trichosanthis. The traditional Chinese medicine liniment has the effects of clearing away heat and toxic materials, dispersing blood stasis, relieving swelling and pain and the like. The traditional Chinese medicine composition is widely used for eczema, acne, psoriasis, erysipelas, paronychia, soft tissue injury, acute cellulitis, acute suppurative lymphadenitis, perianal abscess, phlebitis, external humeral epicondylitis, gonarthromeningitis, swelling after fracture, burn and the like clinically.